We put inspiration into practice, finding viable solutions to complex challenges.
Great ideas are our starting point.
Research focus
Seminars in Translational Science
Our next invited speaker will be Prof. Dr Rajkumar Savai from the Justus Liebig University in Giessen. He is going to join us at TRON on November 21st, 2024. We are looking forward to his talk “Neighbourhood watch in lung cancer: How immune cells and microenvironment interactions shape tumor outcome” and to exchange our scientific insights.
We are TRON
TRON is an independent non-profit translational research organization. We pursue new diagnostics and drugs for the treatment of diseases with high medical need. We apply our transdisciplinary competencies in genomics and immunology to develop novel platforms for the identification and validation of ‘omics’-based biomarkers, to modulate immune system components for use in personalized therapies. Collaborating with academia and industry, TRON executes research at the leading edge to support innovative drug design for human health.
Our new research building
Our new research building is currently under construction on the grounds of Mainz University Medical Center according to a concept by Nickl und Partner architects. This envisions a modern, light-flooded building with laboratory and office areas as well as communication zones with up to 10,800 m² of usable space, which will be integrated into the adjacent green areas and the listed Fichte settlement. As a result of intensive coordination with the city of Mainz and all parties involved, construction preparations have been initiated in record time.
Our Research Focus
TRON conducts collaborative research on disease genomics and therapeutic modulation of the immune system. Specializing in cancer immunology and genomics, our research teams develop tailored bioinformatic and novel biostatistical approaches to identify and characterize disease-relevant molecular targets. We design and improve cutting edge technologies for biomarker discovery and biopharmaceutical development, including platforms for immune-based therapies such as RNA vaccines and cellular therapies.
Target Discovery and Validation
Personalized Therapy Development
Preclinical Vaccine Development
Cellular Therapy Development
Supported by
